Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11091577 | 0.75 | ABL1 (0.42) | MAPTMAPK1HSD17B10RAB9AKMT2A | |
| SCHEMBL10370490 | 0.73 | RAB9A (0.49) | ABCB11HDAC6MAPTMAPK1ALOX12 | |
| SCHEMBL10370533 | 0.71 | ABCB11 (0.47) | ABCB11HDAC6MAPTMAPK1ALOX12 | |
| SCHEMBL10371186 | 0.71 | ABCB11 (0.47) | ABCB11HDAC6MAPTMAPK1ALOX12 | |
| SCHEMBL10656731 | 0.70 | ABL1 (0.66) | MAPTMAPK1HSD17B10RAB9AKMT2A | |
| SCHEMBL10418606 | 0.68 | MEN1 (0.54) | ABCB11HDAC6MAPTMAPK1RAB9A | |
| SCHEMBL10418599 | 0.68 | NPC1 (0.46) | ABCB11HDAC6MAPTMAPK1ALOX12 | |
| SCHEMBL9479393 | 0.67 | RAB9A (0.81) | MAPTMAPK1ALOX12HSD17B10RAB9A | |
| SCHEMBL316390 | 0.67 | RAB9A (0.81) | MAPTMAPK1ALOX12HSD17B10RAB9A | |
| SCHEMBL9555351 | 0.67 | MEN1 (0.56) | ABCB11HDAC6MAPTMAPK1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0127371-B1 | 1,N-DIARYL-4,5-DIHYDRO-1H-PYRAZOL-3-AMINES, COMPOSITIONS CONTAINING THEM AND METHODS FOR THEIR PREPARATION | FISONS plc (GB) | 1990-11-22 | — | — | EP | claimed |
| US-4956378-A | 4,5-dihydro pyrazole compounds | FISONS PLC (GB) | 1990-09-11 | — | — | US | claimed |
| EP-0127371-A2 | 1,N-diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions containing them and methods for their preparation | FISONS plc (GB) | 1984-12-05 | — | — | EP | claimed |
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-4956378-A | 4,5-dihydro pyrazole compounds | FISONS PLC (GB) | 1990-09-11 | — | — | US | disclosed |
| EP-0178035-B1 | ANTI-INFLAMMATORY 1,N-DIARYLPYRAZOL-3-AMINES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | FISONS plc (GB) | 1990-01-03 | — | — | EP | disclosed |
| US-4824859-A | Pyrazoline compounds compositions and use | FISONS PLC. (GB) | 1989-04-25 | — | — | US | disclosed |
| US-4810719-A | Anti-inflammator 1,n-diarylpyrazol-3-amines | FISONS PLC (GB) | 1989-03-07 | — | — | US | disclosed |
| EP-0127371-A2 | 1,N-diaryl-4,5-dihydro-1H-pyrazol-3-amines, compositions containing them and methods for their preparation | FISONS plc (GB) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | ABCB11 3731/4885HDAC6 1874/4885MAPT 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.